



CARDIOVASCULAR RISK BEFORE AND AFTER SURGICAL TREATMENT OF SEVERE OBESITY

RISCO CARDIOVASCULAR PRÉ E PÓS-TRATAMENTO CIRÚRGICO DA OBESIDADE GRAVE

Lilian **CARDIA**¹*, Alexandre Viera **GADDUCCI**¹*, Denis **PAJECKI**¹*, Marco Aurelio **SANTO**¹*, Roberto **DE CLEVA**¹*

ABSTRACT – BACKGROUND: Obesity is a predisposing factor for serious comorbidities, particularly those related to elevated cardiovascular mortality. The atherogenic index of plasma (AIP) has been shown to be a useful indicator of patients with insulin resistance. **AIMS:** The aim of this study was to assess cardiovascular risk before and after surgical treatment of obesity. **METHODS:** A total of 615 patients undergoing bariatric surgery between 2007 and 2012 were evaluated using the analysis of electronic records (triglyceride/high-density lipoprotein cholesterol) before and after surgery. The AIP levels >3.5 mg/dL for men and >2.5 mg/dL for women were insulin-resistant and predisposed to cardiovascular events. **RESULTS:** A total of 117 men had an AIP >3.5 mg/dL during the preoperative period, 13.5% during the early postoperative period, 14.3% during the intermediate period, and 18.2% during the late postoperative period. Among 498 women, 56.2% had an AIP >2.5 mg/dL before surgery, 17.9% in early postoperative period, 13.5% in the intermediate period, and 11.4% in the late period. **CONCLUSIONS:** Bariatric surgery resulted in a significant effect on the AIP, insulin resistance, metabolic syndrome, and therefore, the risk of cardiovascular diseases.

HEADINGS: Obesity. Bariatric Surgery. Insulin Resistance. Metabolic Syndrome. Lipoproteins.

RESUMO – RACIONAL: A obesidade é fator predisponente para patologias potencialmente graves, destacando-se as relacionadas a uma maior mortalidade cardiovascular. O índice aterogênico plasmático (TG/HDL-c) revelou ser um indicador prático, não invasivo e com boa acurácia para identificar pacientes com resistência à insulina, principal componente da síndrome metabólica, além de preditor independente para o desenvolvimento de doenças cardiovasculares. **OBJETIVOS:** Avaliar risco cardiovascular antes e após o tratamento cirúrgico da obesidade. **MÉTODOS:** Foram estudados 615 pacientes submetidos à cirurgia bariátrica, no período de 2007 a 2012, através da análise dos registros eletrônicos (triglicérides, HDL-c, LDL-c e colesterol total) antes e após a cirurgia. Aqueles que apresentaram índice aterogênico plasmático >3,5 mg/dl e 2,5 mg/dl, respectivamente, para homens e mulheres, foram considerados resistentes à insulina e com alto risco de doença cardiovascular. **RESULTADOS:** Entre 117 homens, 53% apresentaram índice aterogênico plasmático >3,5 mg/dl no período pré-operatório, 13,5% no pós-operatório precoce, 14,3% no intermediário e 18,2% no tardio. Entre 498 mulheres, 56,2% apresentaram índice aterogênico plasmático >2,5 mg/dl no pré-operatório, 17,9% no pós-operatório precoce, 13,5% no intermediário e 11,4% no tardio. **CONCLUSÕES:** A intervenção cirúrgica para o tratamento da obesidade promoveu impacto significativo na relação TG/HDL-c, na resistência à insulina, na síndrome metabólica e, conseqüentemente, no risco de doenças cardiovasculares.

DESCRIPTORIOS: Obesidade. Cirurgia Bariátrica. Resistência à Insulina. Síndrome Metabólica. Lipoproteínas.

Central Message

Several diseases are associated with obesity, particularly those related to elevated cardiovascular mortality, such as systemic arterial hypertension, type II diabetes mellitus, dyslipidemia, and metabolic syndrome, which have a direct impact on morbidity and mortality. Insulin resistance (IR) is a fundamental component of metabolic syndrome and an independent predictor of the onset of cardiovascular diseases. IR is closely linked to the degree of obesity, with a notable improvement after weight loss. Bariatric and metabolic surgery has been standardized as a treatment for severe obesity and has been shown to be beneficial for weight reduction, remission of comorbidities, reduced risk of mortality, increased longevity, and improved quality of life.

Perspectives

The non-invasive predictors for the development of cardiovascular disease, such as the atherogenic index of plasma, may be useful for monitoring and determining the risk of patients with severe obesity on long-term follow-up.

[instagram.com/revistaabcd/](https://www.instagram.com/revistaabcd/) twitter.com/revista_abcd [facebook.com/Revista-ABCD-109005301640367](https://www.facebook.com/Revista-ABCD-109005301640367) [linkedin.com/company/revista-abcd](https://www.linkedin.com/company/revista-abcd)

From ¹Universidade de São Paulo, Faculty of Medicine, Department of Gastroenterology – São Paulo (SP), Brazil.

How to cite this article: Cardia L, Gadducci AV, Pajeci D, Santo MA, de Cleve R. Cardiovascular risk before and after surgical treatment of severe obesity. Arq Bras Cir Dig. 2024;37:e1860. <https://doi.org/10.1590/0102-6720202400066e1860>.

Correspondence:
Lilian Cardia.
E-mail: liliancardia@gmail.com;
roberto.cleva@hc.fm.usp.br

Financial source: None
Conflict of interests: None
Received: 06/17/2024
Accepted: 11/08/2024

Editorial Support: National Council for Scientific and Technological Development (CNPq).

INTRODUCTION

According to the World Health Organization, obesity and overweight are among the largest epidemics of the century. It is estimated that around 2 billion adults around the world are overweight, and beyond 700 million have obesity²⁷. The National Health Survey (PNS, 2020) in Brazil confirms the prevalence of obesity among women (29.5%) and men (21.8%)⁴.

Obesity is a complex and multifactorial disease characterized by excessive accumulation of fat with potentially serious comorbidities. It exhibits a wide interaction between genetic and environmental factors with significant psychological and social dimensions¹⁸.

Several comorbidities are associated with obesity, especially those related to higher cardiovascular mortality, such as systemic arterial hypertension, type II diabetes mellitus, dyslipidemia, and metabolic syndrome (MetS). These conditions have a direct impact on morbidity and mortality^{5,12}.

Clinical treatments of severe obesity had little effectiveness, with a recurrence of up to 95%²⁵. For these patients, bariatric and metabolic surgery is considered the treatment of choice due to significant weight loss and remission of associated diseases, reducing the risk of mortality and improving quality of life⁷.

Insulin resistance (IR) is one of the main components of MetS and an independent predictor of cardiovascular diseases (CVDs)¹⁷, hepatic steatosis, and steatohepatitis (metabolic associated steatotic liver disease)²¹. IR is related to the degree of obesity, with improvement observed after weight loss¹⁰. High levels of triglycerides (TG) and a decrease in high-density lipoprotein cholesterol (HDL-c) are frequent consequences of IR³.

The atherogenic index of plasma (AIP — the TG/HDL-c ratio) identifies patients with IR and MetS^{8,14,23}. A TG/HDL-c ratio >3.5 mg/dL has been considered ideal for identifying insulin-dependent patients with a sensitivity and specificity comparable to the criteria proposed for diagnosing MetS¹⁶. Age and gender factors are equally important and should be considered when using the TG/HDL-c ratio to assess cardiovascular risk²⁶. Salazar et al. suggest that men and women with a TG/HDL-c ratio higher than 3.5 and 2.5 mg/dL, respectively, had the worst cardiovascular outcomes²⁰.

The aim of this study was to assess cardiovascular risk before and after surgical treatment of severe obesity.

METHODS

The retrospective study evaluated electronic records of 615 individuals who underwent metabolic surgery in a Bariatric and Metabolic Surgery Unit of the University of Sao

Paulo Medical School between 2007 and 2012. TG and HDL-c data were collected from the following periods: preoperative (PREOP), early postoperative (EARLY PO), between 6 and 12 months, intermediate postoperative (INTER PO), between 12 and 24 months, and late postoperative (LATE PO), between 24 and 36 months after surgery.

The TG/HDL-c ratio (AIP) was calculated from the plasma TG and HDL-c values (in mg/dL) for each period. The AIP was analyzed based on gender²⁶. Men and women with an AIP >3.5 and 2.5 mg/dL, respectively, were considered insulin-resistant and at high risk of developing CVD.

The research was approved by the Research Ethics Committee of the University of Sao Paulo Medical School (number 03006112.6.0000.0068).

Statistics were conducted using Statistical Package for the Social Sciences (SPSS) 12 (SPSS, Chicago, Illinois). For continuous variables, the data were presented as means and standard deviation, while for categorical variables, they were presented as percentages. The Mc-Nemar test was utilized to evaluate the comparison between the periods examined. The statistical significance was determined to be 5% (p<0.05).

RESULTS

The AIP was calculated for 615 patients with severe obesity before bariatric surgery (Table 1). The mean TG/HDL was 3.6±2.7 in the PREOP, 1.94±1.3 in the EARLY PO, 1.8±1.5 in the INTER PO and 1.7±1.2 in the LATE PO (Table 1). Of the 117 men evaluated in the PREOP, 62 patients (53%) had AIP >3.5 mg/dL (mean 7.1±3.7), indicating the presence of IR and MetS. Of the 52 patients studied in the EARLY PO, seven patients (13.5%) had AIP >3.5 mg/dL (mean 6.0±1.5). In the INTER PO, among 35 patients evaluated, five patients (14.3%) had AIP >3.5 mg/dL (mean 5.7±2.3). In the LATE PO, among 22 patients evaluated, four patients (18.2%) had AIP >3.5 mg/dL (mean 6.4±1.8). There was a significant decrease in the number of patients with MetS and a high risk of CVD between the PREOP and EARLY PO periods (p<0.001), between the PREOP and INTER PO periods (p<0.001), and between the PREOP and LATE PO periods (p=0.016).

Of the 498 women evaluated in PREOP, 280 patients (56.2%) had AIP >2.5 mg/dL (mean 4.5±2.1). During the EARLY PO, among 263 patients evaluated, 47 patients (17.9%) had AIP >2.5 mg/dL (mean 3.8±1.7), resulting in a significant decrease in MetS and high CVD risk. Of the 192 patients evaluated during INTER PO, 26 patients (13.5%) had AIP >2.5 mg/dL (mean 4.3±2.5). Among 114 patients evaluated in the LATE PO, 13 patients (11.4%) had AIP >2.5 mg/dL (mean 3.6±1.2). There was a significant decrease in the number of patients

Table 1 - Atherogenic index of plasma before and after surgical treatment for obesity.

	PREOP			EARLY PO				INTER PO				LATE PO			
	Md	%	95%CI	Md	%	95%CI	p-value	Md	%	95%CI	p-value	Md	%	95%CI	p-value
Male (n)	117			52					35				22		
TG/HDL-c ≥3.5	7.1±3.7	53.0	44.0–61.8	6.0±1.5	13.5	6.5–25.7	<0.001	5.7±2.3	14.3	5.9–30.0	<0.001	6.4±0.5	18.2	6.9–39.3	0.016
TG/HDL-c ≤3.5	2.4±0.7			1.6±0.7					1.6±0.8				1.2±0.5		
Female (n)	498			263					192				114		
TG/HDL-c ≥2.5	4.5±2.1	56.2	51.8–60.5	3.8±1.7	17.9	13.7–23.0	<0.001	4.3±2.5	13.5	9.4–19.2	<0.001	3.6±1.2	11.4	6.7–18.7	<0.001
TG/HDL-c ≤2.5	1.7±0.5			1.5±0.5					1.3±0.5				1.4±0.5		


Results are expressed as mean and SD. PREOP: preoperative period; EARLY PO: early postoperative period; INTER PO: intermediate postoperative period; LATE PO: late postoperative period; CI: confidence interval; Md: median.

with MetS and a high risk of CVD between the PREOP and EARLY PO periods ($p < 0.001$), between the PREOP and INTER PO periods ($p < 0.001$), and between the PREOP and LATE PO periods ($p < 0.001$).

The percentage evaluation of patients during the surgical periods is shown in Figures 1 and 2.


DISCUSSION

Metabolic alterations, such as IR and hyperinsulinemia, can lead to changes in TG and total cholesterol. These changes can predispose to atherosclerotic disease and an increased risk of cardiovascular events. Studies indicate that the AIP, determined by routine tests, has a strong correlation with cardiovascular risk and acute myocardial infarction regardless of gender^{11,13,15}.



TG/HDL: triglyceride/high-density lipoprotein cholesterol.

Figure 1 - Percentage of male patients with an atherogenic index of plasma >3.5 mg/dL in preoperative, early postoperative, intermediate postoperative, and late postoperative periods. The bars represent the confidence interval (95% CI).



TG/HDL: triglyceride/high-density lipoprotein cholesterol.

Figure 2 - Percentage of female patients with an atherogenic index of plasma >2.5 mg/dL in preoperative, early postoperative, intermediate postoperative, and late postoperative periods. The bars represent the confidence interval (95% CI).

The relationship with the development of atherosclerosis from high concentrations of lipoproteins results in an increase in LDL-c¹⁹. It has been demonstrated that AIP is an indicator of the progression and severity of coronary lesions⁶. AIP is also important for identifying patients with IR and MetS. Elevated TG and reduced HDL-c levels are independent risk factors for coronary heart disease. Additionally, these alterations are observed in the presence of IR⁹.

Recent evidence suggests that obesity-associated coronary heart disease may be a direct outcome of excessive fat and visceral adiposity, through mechanisms involving a low-grade inflammatory state, endothelial dysfunction, and regulation of pro-inflammatory cytokines².

Our study shows that individuals with obesity in the preoperative period had a high AIP (53% of men and 56.2% of women), demonstrating the high prevalence of IR, MetS, and increased cardiovascular risk in this population.

Nevertheless, we can observe a notable decrease in IR, MetS, and cardiovascular risk assessed at other times during the analysis, which persists for 36 months after surgical treatment for obesity.

The percentage decrease is similar between men (53% in PREOP, 13.5% in EARLY PO, 14.3% in INTER PO, and 18.2% in LATE PO) and women (56% in PREOP, 17.9% in EARLY PO, 13.5% in INTER PO, and 11.4% in LATE PO), showing the effectiveness of bariatric surgery in controlling dyslipidemia.

The weight loss induced by bariatric surgery is accompanied by a reduction in cardiovascular risk and mortality^{1,22}. Vest et al. conducted an analysis of 73 studies involving 19,543 patients, including 76% women. The findings revealed an average reduction in excess weight of 54%, and improvement in hypertension, diabetes, and dyslipidemia in 44%, 24%, and 44% of patients, respectively, with an average follow-up of 57.8 months²⁴.

Our research has some limitations. The current investigation is a retrospective study. Second, the presence of comorbidities such as hypertension, diabetes, and the use of medication for dyslipidemia were not included. Information on potential risk factors for CVD such as diet, physical activity, genetic factors, and demographic and anthropometric variables was not collected during our study. Another limitation is the decreasing number of patients in the late follow-up of bariatric surgery.

CONCLUSIONS

Bariatric surgery was associated with a significant decrease in AIP, reducing cardiovascular risk in individuals with severe obesity. This reduction persists for at least 3 years after surgery.

REFERENCES

1. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Cardiovascular benefits of bariatric surgery in morbidly obese patients. *Obes Rev*. 2011;12(7):515-24. <https://doi.org/10.1111/j.1467-789X.2010.00831.x>
2. Bays HE. Adiposopathy is "sick fat" a cardiovascular disease? *J Am Coll Cardiol*. 2011;57(25):2461-73. <https://doi.org/10.1016/j.jacc.2011.02.038>
3. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. *Diabetes Care*. 2007;30(2):318-24. <https://doi.org/10.2337/dc06-0919>

4. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Saúde prepara ações para controle do excesso de peso e da obesidade. Brasília: Ministério da Saúde, 2020. Available at: <https://www.gov.br/saude/pt-br/assuntos/noticias/2020/outubro/saude-prepara-acoes-para-controle-do-excesso-de-peso-e-da-obesidade>. Accessed: Oct. 06, 2024.
5. Cremonesi MC, Duarte-Guerra L, Pajecki D, Santo MA, Lotufo Neto F, Wang YP. Validity of the Brazilian-Portuguese version of Moorehead-Ardelt quality of life questionnaire II among patients with severe obesity. *Arq Bras Cir Dig*. 2023;36:e1767. <https://doi.org/10.1590/0102-672020230049e1767>
6. Luz PL, Favarato D, Faria-Neto Jr. JR, Lemos P, Chagas ACP. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. *Clinics (Sao Paulo)*. 2008;63(4):427-32. <https://doi.org/10.1590/s1807-59322008000400003>
7. De Luca M, Angrisani L, Himpens J, Busetto L, Scopinaro N, Weiner R, et al. Indications for surgery for obesity and weight-related diseases: position statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). *Obes Surg*. 2016;26(8):1659-96. <https://doi.org/10.1007/s11695-016-2271-4>
8. Moura EGH, Orso IRB, Martins BC, Lopes GS, Oliveira SL, Galvão-Neto MP, et al. Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. *Obes Surg*. 2011;21(7):941-7. <https://doi.org/10.1007/s11695-011-0387-0>
9. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. *N Engl J Med*. 1996;334(15):952-7. <https://doi.org/10.1056/NEJM199604113341504>
10. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. *Diabetes Care*. 2009;32(3):514-20. <https://doi.org/10.2337/dc08-1762>
11. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. *Circulation*. 1997;96(8):2520-5. <https://doi.org/10.1161/01.cir.96.8.2520>
12. Giampaoli S, Stamler J, Donfrancesco C, Panico S, Vanuzzo D, Cesana G, et al. The metabolic syndrome: a critical appraisal based on the CUORE epidemiologic study. *Prev Med*. 2009;48(6):525-31. <https://doi.org/10.1016/j.ypmed.2009.03.017>
13. Hanak V, Munoz J, Teague J, Stanley Jr A, Bittner V. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. *Am J Cardiol*. 2004;94(2):219-22. <https://doi.org/10.1016/j.amjcard.2004.03.069>
14. Li YW, Kao TW, Chang PK, Chen WL, Wu LW. Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study. *Sci Rep*. 2021;11(1):9900. <https://doi.org/10.1038/s41598-021-89307-z>
15. Matos LN, Giorelli G, Dias CB. Perfil clínico, metabólico e antropométrico de indivíduos obesos em hospital terciário da cidade de São Paulo. *Rev Bras Clin Med*. 2011;9(3):179-84.
16. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? *Am J Cardiol*. 2005;96(3):399-404. <https://doi.org/10.1016/j.amjcard.2005.03.085>
17. Melikian N, Chowienczyk P, MacCarthy PA, Williams IL, Wheatcroft SB, Sherwood R, et al. Determinants of endothelial function in asymptomatic subjects with and without the metabolic syndrome. *Atherosclerosis*. 2008;197(1):375-82. <https://doi.org/10.1016/j.atherosclerosis.2007.06.009>
18. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser*. 2000;894:i-xiii, 1-253. PMID: 11234459.
19. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. *Arterioscler Thromb Vasc Biol*. 1997;17(12):3542-56. <https://doi.org/10.1161/01.atv.17.12.3542>
20. Salazar MR, Carbajal HA, Espeche WG, Leiva Sisniegues CE, Balbín E, Dulbecco CA, et al. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. *Am J Cardiol*. 2012;109(12):1749-53. <https://doi.org/10.1016/j.amjcard.2012.02.016>
21. Silva MBB, Tustumi F, Dantas ACB, Miranda BCJ, Pajecki D, DE-Clewa R, et al. Obesity and severe steatosis: the importance of biochemical exams and scores. *Arq Bras Cir Dig*. 2022;34(4):e1626. <https://doi.org/10.1590/0102-672020210002e1626>
22. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. *JAMA*. 2012;307(1):56-65. <https://doi.org/10.1001/jama.2011.1914>
23. Tong PC, Kong AP, So WY, Yang X, Ho CS, Ma RC, et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. *Diabetes Care*. 2007;30(5):1206-11. <https://doi.org/10.2337/dc06-1484>
24. Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. *Heart*. 2012;98(24):1763-77. <https://doi.org/10.1136/heartjnl-2012-301778>
25. Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. *Obes Res*. 2004;12 Suppl:151S-62S. <https://doi.org/10.1038/oby.2004.282>
26. Wakabayashi I. Influence of age and gender on triglycerides-to-HDL-cholesterol ratio (TG/HDL ratio) and its association with adiposity index. *Arch Gerontol Geriatr*. 2012;55(3):729-34. <https://doi.org/10.1016/j.archger.2012.07.001>
27. World Health Organization. Obesity and overweight. Geneva: WHO; 2020. Available at: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>. Accessed: Oct 06, 2024.